442 results on '"Voest, E.E."'
Search Results
2. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
3. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics
4. Grasping the Complexity of Anti-Tumor Immunity: Looking at T cells and beyond
5. Clinical implementation of new diagnostic modalities in the era of precision oncology: Path to Precision
6. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
7. Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.
8. Bridging the gap: Implementation of whole genome sequencing in routine clinical care
9. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
10. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study
11. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
12. Gamma delta T cells are effectors of immunotherapy in cancers with HLA class I defects
13. 124P Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort
14. 1045P Comprehensive genomic profiling to guide immunotherapy in lung cancer
15. 1350P Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations
16. 257P Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP)
17. 1673P Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing
18. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
19. 1312O From regulating off-label use to creating an environment for drug repurposing in oncology
20. 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
21. 733MO γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
22. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
23. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
24. Improving immunotherapy responses in gastrointestinal cancers
25. Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients
26. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
27. Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
28. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
29. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography–tandem mass spectrometry
30. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
31. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
32. 54P Identification of patient-specific T-cell neoantigens through HLA-agnostic genetic screens
33. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
34. 1133P Whole genome sequencing can classify diagnostically challenging tumors
35. 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
36. 1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
37. 1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
38. 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
39. Medical oncology patients’ preferences with regard to health care: development of a patient-driven questionnaire
40. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
41. Genomics-based Precision Medicine for Patients with Cancer
42. On the road to personalized immunotherapy: an unexpected journey
43. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
44. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry
45. Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back
46. Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing
47. Personalized medicine for patients with advanced cancer. Towards tailored anti-cancer treatment
48. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system
49. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
50. Tumor organoids as a personalized model of human cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.